DPP-4 drugs are less effective also on other metrics. Would be far more interesting to see the comparison of SGLT-2 inhibitors vs GLP-1 agonists.
For some reason GLP-1 drugs are not that popular in Korea (and still not prescribed just for the weight loss), so that may explain why these researchers haven't done that.
For some reason GLP-1 drugs are not that popular in Korea (and still not prescribed just for the weight loss), so that may explain why these researchers haven't done that.